The immunogenicity of ReFacto AF (moroctocog alfa AF-CC) in previously untreated patients with haemophilia A in the United Kingdom.

M C MathiasP W CollinsB P PalmerElizabeth A ChalmersJ AlameluM RichardsA WillCharles R M Haynull null

Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2018)

Inhibitor incidence in a single country population of ReFacto AF PUPs was similar to that previously described. Low- and high-titre inhibitors were detected after a similar number of EDs, contrasting with previous data, probably reflecting standardized inhibitor monitoring within the United Kingdom.

Keyphrases

atrial fibrillation
risk factors
electronic health record
cross sectional
replacement therapy
machine learning
artificial intelligence